Article

In 2000, a French consensus conference proposed guidelines for the treatment of
Parkinson's disease (PD). Since then, new drugs have been concocted, new studies
have been published and clinicians have become aware of some drug-induced adverse
effects that were little known in the past. This has led us to reconsider the
recommendations published 16 years ago. Thus, the aim of the present review is to
present the recent data related to the different medications and
non-pharmacological approaches available for PD, with a special focus on
early-stage PD. Levodopa (LD), dopamine agonists (DAs),
catechol-O-methyltransferase inhibitors (COMT-Is), anticholinergics, monoamine
oxidase inhibitors (MAOB-Is)
and amantadine have been considered, and their
efficacy and safety for both motor as well as non-motor aspects are reported
here. This has led to our proposal for a revised therapeutic strategy for the
initiation of treatment in newly diagnosed PD patients, based on the available
literature and the relative benefits/side effects balance.
CI - Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS